Beth Seidenberg, M.D., is the founding managing director of Westlake Village BioPartners. She was a general partner at Kleiner Perkins and has incubated and invested in more than 40 biotech companies across many therapeutic areas and modalities since 2005. She currently sits on the public company boards of Vera Therapeutics, Progyny, Kyverna Therapeutics, Sagimet Biosciences, and Acelyrin.
Previously, Seidenberg served in leadership roles at Bristol-Myers Squibb, Merck Research Laboratories and Amgen, where she was chief medical officer and head of global development. In these roles, she developed new treatments for AIDS, arthritis, asthma, cancer, psoriasis, cardiovascular, metabolic, neurological, and renal disorders for more than 20 years, introducing 10 innovative products to market. Seidenberg received her M.D. from the University of Miami School of Medicine, completed her medical residency at Johns Hopkins University and George Washington University, and her fellowship at the National Institutes of Health. She received a B.A. in biology and anthropology from Barnard College.